Goldman Sachs Upgrades Danaher, Downgrades Waters | GenomeWeb

NEW YORK (GenomeWeb News) – Goldman Sachs on Monday upgraded shares of Danaher's stock, while it downgraded Waters' shares.

Analyst Isaac Ro upgraded Danaher to a Buy rating from a prior rating of Neutral and raised the 12-month price target on the company's stock to $88 from $75. He also downgraded Waters to a Neutral rating from Buy, and reduced the price target on its stock to $107 from $117.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.